Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma

Summary

This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable.

Timeline

Start

2022-09-09

Primary completion

2023-08-08

Completion

2024-01-08

Outcome

Outcome not reported

Stopped (Business): “The decision is not based on emerging safety or efficacy concerns but on strategic reasons related to the changing and competitive treatment options in Multiple Myeloma”

Drugs

Indications